Oncolytic Viruses for Canine Cancer Treatment
Oncolytic virotherapy has been investigated for several decades and is emerging as a plausible biological therapy with several ongoing clinical trials and two viruses are now approved for cancer treatment in humans. The direct cytotoxicity and immune-stimulatory effects make oncolytic viruses an int...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/10/11/404 |
| _version_ | 1797706210890219520 |
|---|---|
| author | Diana Sánchez Gabriela Cesarman-Maus Alfredo Amador-Molina Marcela Lizano |
| author_facet | Diana Sánchez Gabriela Cesarman-Maus Alfredo Amador-Molina Marcela Lizano |
| author_sort | Diana Sánchez |
| collection | DOAJ |
| description | Oncolytic virotherapy has been investigated for several decades and is emerging as a plausible biological therapy with several ongoing clinical trials and two viruses are now approved for cancer treatment in humans. The direct cytotoxicity and immune-stimulatory effects make oncolytic viruses an interesting strategy for cancer treatment. In this review, we summarize the results of in vitro and in vivo published studies of oncolytic viruses in different phases of evaluation in dogs, using PubMed and Google scholar as search platforms, without time restrictions (to date). Natural and genetically modified oncolytic viruses were evaluated with some encouraging results. The most studied viruses to date are the reovirus, myxoma virus, and vaccinia, tested mostly in solid tumors such as osteosarcomas, mammary gland tumors, soft tissue sarcomas, and mastocytomas. Although the results are promising, there are issues that need addressing such as ensuring tumor specificity, developing optimal dosing, circumventing preexisting antibodies from previous exposure or the development of antibodies during treatment, and assuring a reasonable safety profile, all of which are required in order to make this approach a successful therapy in dogs. |
| first_indexed | 2024-03-12T05:47:54Z |
| format | Article |
| id | doaj.art-c06b5ce941ab4159b92bd90ad7045342 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T05:47:54Z |
| publishDate | 2018-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c06b5ce941ab4159b92bd90ad70453422023-09-03T05:30:17ZengMDPI AGCancers2072-66942018-10-01101140410.3390/cancers10110404cancers10110404Oncolytic Viruses for Canine Cancer TreatmentDiana Sánchez0Gabriela Cesarman-Maus1Alfredo Amador-Molina2Marcela Lizano3Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoDepartment of Hematology, Instituto Nacional de Cancerología, Mexico City 14080, MexicoUnidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoUnidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoOncolytic virotherapy has been investigated for several decades and is emerging as a plausible biological therapy with several ongoing clinical trials and two viruses are now approved for cancer treatment in humans. The direct cytotoxicity and immune-stimulatory effects make oncolytic viruses an interesting strategy for cancer treatment. In this review, we summarize the results of in vitro and in vivo published studies of oncolytic viruses in different phases of evaluation in dogs, using PubMed and Google scholar as search platforms, without time restrictions (to date). Natural and genetically modified oncolytic viruses were evaluated with some encouraging results. The most studied viruses to date are the reovirus, myxoma virus, and vaccinia, tested mostly in solid tumors such as osteosarcomas, mammary gland tumors, soft tissue sarcomas, and mastocytomas. Although the results are promising, there are issues that need addressing such as ensuring tumor specificity, developing optimal dosing, circumventing preexisting antibodies from previous exposure or the development of antibodies during treatment, and assuring a reasonable safety profile, all of which are required in order to make this approach a successful therapy in dogs.https://www.mdpi.com/2072-6694/10/11/404oncolytic viruscanine cancerimmunotherapycanine treatment |
| spellingShingle | Diana Sánchez Gabriela Cesarman-Maus Alfredo Amador-Molina Marcela Lizano Oncolytic Viruses for Canine Cancer Treatment Cancers oncolytic virus canine cancer immunotherapy canine treatment |
| title | Oncolytic Viruses for Canine Cancer Treatment |
| title_full | Oncolytic Viruses for Canine Cancer Treatment |
| title_fullStr | Oncolytic Viruses for Canine Cancer Treatment |
| title_full_unstemmed | Oncolytic Viruses for Canine Cancer Treatment |
| title_short | Oncolytic Viruses for Canine Cancer Treatment |
| title_sort | oncolytic viruses for canine cancer treatment |
| topic | oncolytic virus canine cancer immunotherapy canine treatment |
| url | https://www.mdpi.com/2072-6694/10/11/404 |
| work_keys_str_mv | AT dianasanchez oncolyticvirusesforcaninecancertreatment AT gabrielacesarmanmaus oncolyticvirusesforcaninecancertreatment AT alfredoamadormolina oncolyticvirusesforcaninecancertreatment AT marcelalizano oncolyticvirusesforcaninecancertreatment |